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Abstract 
We report a case of a male patient with autoimmune pancreatitis in whom biochemical 
examination revealed high plasma chromogranin A concentrations, histological 
demonstration of a small lymphocytic infiltrate and rapid decrease in size of the 
pancreatic mass following short-lasting therapy with methylprednisolone. To our 
knowledge, this is the first patient with autoimmune pancreatitis who had a 
simultaneous increase of serum chromogranin A levels, circulating and urinary serotonin 
concentrations and urine 5-hydroxyindoleacetic acid concentrations. This is one of the 
few cases of mass forming pancreatitis with small lymphocytic infiltrate found in a 
Caucasian patient and rapid decrease in size of the pancreatic mass following short-
lasting therapy with methylprednisolone. 
 
Introduction 
It is well known that the frequency of new diagnoses of autoimmune pancreatitis has 
increased in the past few years [1, 2]. Autoimmune pancreatitis is characterized by diffuse 
or focal pancreatic swelling with a narrowing of the pancreatic duct and/or common bile 
duct. Elevated circulating IgG or IgG4 concentrations seem to be the hallmark of 
sclerosing pancreatitis [3] as well as the histological findings of lymphoplasmacytic 
infiltration, especially concentrated on the pancreatic ducts [4]. From a therapeutic point  
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of view, steroids are a well-known efficacious treatment of autoimmune pancreatitis; 
however we do not have sufficient information about the duration of this treatment [5]. 
We herein report the case of a patient with autoimmune pancreatitis in whom 
biochemical examination revealed high plasma chromogranin A concentration, 
histological demonstration of a small lymphocytic infiltrate and disappearance of the 
pancreatic mass following therapy with methylprednisolone. 
Case Report 
CA, a 71-year-old Caucasian male, was admitted in October 2006 to the emergency department of 
our hospital for the duration of one month for mild epigastric pain associated with 5 days of jaundice. 
The patient was a heavy smoker (20 cigarettes per day for 50 years) and slight drinker (40 g of alcohol 
per day for 50 years). His past history included vitiligo, diagnosed at 40 years of age, chronic gastritis 
(histological diagnosis), chronic duodenitis, duodenal ulcer and hypertension. He chronically consumed 
proton pump inhibitors and ACE inhibitors. 
Biochemical examination revealed an increase in serum concentrations of bilirubin (total bilirubin 
9.2 mg/dl), AST (174 U/l, upper reference value 37 U/l), ALT (359 U/l, upper reference value 40 U/l), 
plasma serotonin (2.63 μmol/l, upper reference value 1.14 μmol/l), urinary serotonin (862 μg/g 
creatinine, upper reference limit 110 μg/g creatinine), urinary 5-hydroxyindoleacetic acid (5-HIAA) (8.9 
mg/24 h, upper reference value 8.0 mg/24 h), and chromogranin A (490 U/l, upper reference limit 17 
U/l). Serum amylase, lipase, CEA, and CA 19-9 were within the normal reference values. 
An abdominal ultrasonography showed a hypoechoic mass of about 3 cm in diameter of the head of 
the pancreas with a dilatation of both Wirsung duct and common bile duct. Computer tomography 
confirmed the echographic findings and also showed involvement of the duodenum, superior 
mesenteric artery, and splenic and portal veins; the lesion remained hypodense after contrast medium 
injection (fig. 1). In the following days there was an increase of jaundice and bilirubin reached 12.88 
mg/dl and the patient underwent an ERCP, and an endoscopic sphincterotomy was performed and for 
the suspicion of a pancreatic tumour a wallstent was placed. To reach a diagnosis a core biopsy of the 
pancreas mass was performed. Sample tissue was fixed in 10% buffered formalin and embedded in 
paraffin. 4-μm-thin sections were cut and stained for haematoxylin-eosin and Giemsa. 
Immunohistochemistry was performed according to the APAAP and EnVision
++ technique [6, 7] and 
the following molecules searched (source in brackets): CD3 (NeoMarkers), CD20 (Dako), CD10 
(NovoCastra), Bcl-6 and IRTA-1 (kindly provided by Prof. B. Falini, University of Perugia), Bcl-2 
(kindly provided by Prof. D. Mason, University of Oxford), and Ki-67/Mib1 (Dako). Histology showed 
fragments of pancreatic tissue whose structure was impaired by fibrotic bundles, replacing normal 
parenchyma with a moderate lymphoid infiltrate. The latter was organized in aggregates, mostly 
composed of small lymphocytes with regular nuclear profile and partially arranged in reactive looking 
follicles with prominent germinal centres; few mast cells and eosinophils were interspersed, while 
plasma cells were rare and located around the lymphoid foci (fig. 2). No lympho-epithelial lesions were 
seen. The residual acinar parenchyma was unremarkable. Immunohistochemistry proved the mixed 
reactive nature of the intra-pancreatic lymphoid infiltrate (CD3–/+, CD20+/–) with benign follicular 
structures that strongly expressed CD20, Bcl-6 and CD10, but not Bcl-2 (fig. 3) with high proliferation 
index in the germinal centres (Ki-67/Mib1), as expected. A diagnosis of autoimmune pancreatitis with 
fibrosis and benign follicular infiltrate consistent with an autoimmune pancreatitis was made. The 
clinical conditions of the patient progressively improved and the patient was discharged from the 
hospital on December 2006. 
In January 2007 a new assessment of biochemical examinations was carried out. Total bilirubin was 
0.99 mg/dl, and AST and ALT returned within the normal reference range. The IgGs were within the 
normal reference values (881 mg/dl, upper reference value 1,600 mg/dl), as well as both IgA (194 mg/dl, 
upper reference value 400 mg/dl) and IgM (32 mg/dl, upper reference value 230 mg/dl), and the 
autoantibodies were not detectable. It is worth noting that plasma concentrations of chromogranin A 
fell within the normal reference range (10 U/l) as well as those of plasma serotonin, urinary serotonin, 
and urinary 5-HIAA. 
To better characterize the pancreatic mass, a contrast enhanced ultrasonography was carried out 
showing a diffuse hypoechoic pattern of the pancreas with late enhancement of the pancreatic lesion 
after contrast medium injection; an echoendoscopy confirmed the hypoechoic mass of 3 cm of diameter  
Case Rep Gastroenterol 2008;2:11–17 
DOI: 10.1159/000113218 
Published online: January 24, 2008  © 2008 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
13
of the head of the pancreas. Because the size of the mass was unchanged from October 2006 and on the 
basis of a histological examination, a diagnosis of autoimmune pancreatitis was made and a treatment 
with methylprednisolone at a dosage of 1 mg/kg was started. After one month of this treatment, the 
patient underwent abdominal contrast enhanced CT which showed a clear decrease in size of the 
pancreatic mass. Six months after steroid treatment, the patient was in good general condition and the 
contrast enhanced CT showed a complete disappearance of the pancreatic mass (fig. 4). 
Discussion 
The case reported presents some features that we consider worth reporting. To our 
knowledge, this is the first case of autoimmune pancreatitis with an increase in plasma 
and urinary serotonin, urinary 5-HIAA and chromogranin A. Why these biological 
parameters returned to normal levels before the steroid treatment is not clear, but the 
initial elevations cannot be related to the therapy, because the patient continued the PPI 
intake. In this case the firm diagnosis came from the histological examination of the 
pancreatic specimen obtained at core biopsy that showed pancreatic tissue whose 
structure was impaired by fibrotic bundles, replacing normal parenchyma with a 
moderate lymphoid infiltrate. The latter was organized in aggregates, mostly composed of 
small lymphocytes with regular nuclear profile and partially arranged in reactive looking 
follicles with prominent germinal centres; few mast cells and eosinophils were 
interspersed, while plasma cells were rare and located around the lymphoid foci. 
Immunohistochemistry proved the mixed reactive nature of the intra-pancreatic 
lymphoid infiltrate with benign follicular structures that strongly expressed CD20, Bcl-6 
and CD10, but not Bcl-2 with high proliferation index in the germinal centres. In our 
experience of 15 cases of autoimmune pancreatitis [8–11], this is the first case of 
autoimmune pancreatitis in whom a predominant T-lymphocyte expression was found. 
Japanese authors reported in the revised classification of 2006 that autoimmune chronic 
pancreatitis may be characterized, other than lymphoplasmacytic infiltrates, also by 
lymphocyte infiltration in which T cells are often predominant, and plasma cells are 
IgG4-positive [12]. Recently they also claimed that patients with neutrophilic infiltration 
in the epithelium of the pancreatic duct reported by American and Italian pathologists 
showed different clinicopathological features from autoimmune pancreatitis defined in 
Japan [13]. The third characteristic of this case is the spontaneous normalization of 
plasma and urinary serotonin, urinary 5-HIAA and chromogranin A. Finally, the 
inflammatory mass disappeared six months after steroid treatment, confirming that early 
introduction of steroid treatment is recommended especially for patients with obstructive 
jaundice associated with autoimmune pancreatitis histologically proven [14, 15] in order 
to avoid the mismanagement of a potentially resectable pancreatic malignancy [16]. 
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Fig. 1. Baseline multidetector computer tomography. a Mass of the head of the pancreas. b Dilatation 
of the main pancreatic duct due to the head pancreatic mass. 
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Fig. 2. a Pancreatic tissue with lymphoid aggregates and fibrotic bundles (haematoxylin-eosin, original 
magnification 100×). b Lymphoid nodules contain small lymphocytes with rare mast cells and plasma 
cells (Giemsa stain, original magnification 200x). 
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Fig. 3. a CD3 staining in the follicle (EnVision
++, original magnification 200×). b CD20 positivity in 
the same follicle (EnVision
++, original magnification 200×). c Ki-67 staining: high proliferation index in 
the germinal centre (EnVision
++, original magnification 200×). d Bcl-2 negativity in the germinal 
centre (APAAP, original magnification 400×). 
 
 
 
Fig. 4. Multidetector computer tomography carried out six months after steroid treatment showing the 
normalization of the pancreatic gland. 
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